High Purity Sex Steroid Hormones Powder Fulvestrant Faslodex CAS 129453-61-8

Quick Detail:

Fulvestrant

Fulvestrant CAS:129453-61-8
Fulvestrant Synonyms: FASLODEX
Fulvestrant Chemical Name:(7a,17b)-7-[9-[(4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol
Fulvestrant Molecular Fomular:C32H47F5O3S
Fulvestrant Molecular Weight:606.77

Fulvestrant Density:1.201 g/cm3
Fulvestrant Melting Point:104-106°C
Fulvestrant Boiling Point:674.8 °C at 760 mmHg
Fulvestrant Appearance:white powder
Fulvestrant Usage:Antineoplastic (hormonal)

Dylan

Email:dylan@ycgmp.com

whats app:+8618826067431

Description:

Fulvestrant Faslodex is a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. It is administered as a once-monthly injection.
Fulvestrant Faslodex is approved to treat breast cancer in postmenopausal women. It is used in patients with estrogen receptor positive breast cancer that has metastasized (spread to other parts of the body) after treatment with other antiestrogens.
Fulvestrant Faslodex is also being studied in the treatment of other types of cancer.

High Purity Sex Steroids Powder Fulvestrant Faslodex CAS 129453-61-8

Applications:

Many breast cancers are stimulated to grow by the female sex hormones oestrogen and progesterone. These breast cancers are called hormone sensitive or hormone receptor positive. Drugs that block the effects of these hormones can slow or stop the growth of the breast cancer cells. Fulvestrante stops oestrogen getting to the cancer cells by blocking oestrogen receptors and reducing the number of receptors the cancer cell has.

Fulvestrante (Faslodex, AstraZeneca) is a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works by down-regulating the estrogen receptor.

Fulvestrante is a selective estrogen receptor down-regulator (SERD). Fulvestrante is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. The dosing schedule for fulvestrante remains under investigation in an attempt to optimize its effectiveness.

Fulvestr